GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood

Rhea-AI Summary

GBS Inc. (Nasdaq: GBS) has completed a clinical study analyzing glucose levels in oral fluids and blood samples at Sutter Health’s Mills-Peninsula Medical Center. The study involved 40 adult subjects with type 2 diabetes, collecting nearly 1400 samples. The company aims to correlate glucose levels from various sample types using validated measurement methods developed with Johns Hopkins University. The results will support future regulatory submissions and guide further clinical studies anticipated in Q4 2022.

Positive

• Completion of clinical study on glucose levels involving 40 subjects with type 2 diabetes.
• Collecting nearly 1400 samples for comprehensive analysis.
• Utilizing independent glucose measurement methods, enhancing credibility.
• Collaboration with Johns Hopkins University for valid measurement methods.
• Data will support future regulatory submissions, strengthening future prospects.

Negative

• None.

• The trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of glucose
  

NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabetes Research Institute of Sutter Health’s Mills-Peninsula Medical Center (MPMC) in San Mateo, California. GBS will perform subsequent statistical analyses of the correlation of glucose levels among these sample types.

Daniel Brown, PhD, CCRC and Head of Clinical Affairs for GBS stated, “While a systematic literature review reveals numerous clinical investigations of salivary glucose levels, we at GBS believe that this is the first clinical study to utilize an independent, validated, traceable reference measurement to characterize glucose in oral fluids. We are privileged to collaborate with the Diabetes Research Institute and Johns Hopkins University to complete this important research and thank them in their support in this study. We look forward to continued statistical analysis of the data generated during this study.”

Key Points to Highlight:

• The clinical study followed an IRB-approved protocol.
• 40 adult subjects with type 2 diabetes were recruited for the study. The subjects represented a distribution of gender and age.
• Nearly 1400 samples of blood and oral fluids were collected and analyzed.
• GBS used independent glucose measurement procedures to quantitate glucose in oral fluids and blood, in order to characterize the degree of agreement among the various sample types.
• GBS engaged with Johns Hopkins University to develop and validate a primary reference method for the measurement of glucose in saliva.
• Analysis of the resulting data will explore the degree of agreement among glucose levels in oral fluid and blood samples by subject and across the entire cohort.
• The Company will provide further details on the analysis in its upcoming earnings press release and on the quarterly conference call.
  

The data generated from this study will become the foundation for building a robust portfolio of prospective clinical evidence,   forming the backbone for future regulatory submissions. There is a shortage of studies of salivary glucose that use independent, validated means of analyzing glucose levels in saliva. The Company anticipates further clinical studies in the fourth quarter of this year and will utilize Saliva Glucose Biosensors fabricated at the Centre for Organic Electronics in New South Wales, Australia.

Forward-Looking Statements:

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, GBS Inc.’s ability to develop and commercialize its diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although GBS, Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. GBS Inc. has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in the Company’s public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

About GBS Inc.

GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes. For more information, please visit https://gbs.inc.

Company Contact:
Alex Arzeno – Vice President of IR & Communications
GBS, Inc.
Investor.Relations@gbs.inc

Investor Contact:
Tim McCarthy – Managing Director
LifeSci Advisors, LLC
Tim@LifeSciAdvisors.com

FAQ

What did GBS Inc. announce on July 13, 2022?

On July 13, 2022, GBS Inc. announced the completion of a clinical study analyzing glucose in oral fluids and blood samples.

How many subjects were involved in the GBS clinical study?

The clinical study involved 40 adult subjects with type 2 diabetes.

What was the main goal of GBS's clinical study?

The main goal was to evaluate the correlation of glucose levels among oral fluids and blood samples.

What is the significance of the collaboration with Johns Hopkins University?

The collaboration aimed to develop and validate independent measurement methods for glucose in saliva.

When can shareholders expect more information from GBS Inc.?

GBS Inc. plans to provide further details during its upcoming earnings press release and quarterly conference call.